CD274 and neoplasm: The study by Kanjanapan Y et al. including various tumor types and with 20% of patients receiving anti-PD-1/PD-L1 combined with other immune-stimulatory molecules found a significantly lower PFS for HPD patients (1.6 vs. 2.8 months, p < 0.001).